Population Bioequivalence (PBE) analysis for in-vitro studies [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2019-05-23 10:50 (1772 d 06:56 ago) – Posting: # 20296
Views: 2,459

Hello kotu,

❝ Population Bioequivalence (PBE) analysis is required for in-vitro studies as per FDA guidance for few products like Iron Sucrose Injection, Ciclosporine Ophthalmic Emulsion, Azelastine Nasal spray etc.


❝ For performing PBE analysis there are two statistical methods

❝ 1. One-sided PBE

❝ 2. Traditional PBE


I am not sure what is meant here, can you elaborate?
How did you see two options for PBE apart from vague hints that applicants may propose their own methods etc?

PBE is well-defined but largely abandoned for in vivo crossover studies. For in vitro trials, your situation, a variant of PBE was introduced in the Budenoside guidance and it is often your method of choice.

❝ If the study is meeting criteria as per one-sided PBE analysis & not meeting the criteria as per the traditional PBE analysis, whether that study will be accepted by regulatory?


Rhetorically, you are testing the question using the method you specified in your protocol prior to conducting the experiment.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
117 visitors (0 registered, 117 guests [including 10 identified bots]).
Forum time: 16:46 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5